// App-Quantinova.ai

349.0 : The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Researchers

Presenter

  • Daniel John Renouf

Principal Investigators

  • Neesha C. Dhani

  • Petr Kavan

  • Derek J. Jonker

  • Alice Chia-chi Wei

  • Tina Hsu

  • Patricia A. Tang

  • Barbara Graham

  • Lisa Gallinaro

  • Tasnia Hasan

  • Weiwei Li

  • Kate Hart

  • Dongsheng Tu

  • Christopher J. O'Callaghan

Medical Centers

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Montreal University, Montreal, QC, Canada

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

  • University of Toronto, Toronto, ON, Canada

  • The Ottawa Hospital, Ottawa, ON, Canada

  • University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada

  • Queen's University, Kingston, ON, CA

  • Queen's University, Kingston, ON, CA

  • Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ticilimumab

  • Gemcitabine

  • Durvalumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02879318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved